Biogen (NASDAQ:BIIB) Stock Price Down 7.3% – Time to Sell?

Biogen Inc. (NASDAQ:BIIB) shares fell 7.3% on Tuesday . The stock traded as low as $192.70 and last traded at $193.7590. 344,619 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 1,268,935 shares. The stock had previously closed at $209.03.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen and Ionis said diranersen produced meaningful reductions in tau biomarkers and showed signs of slowing cognitive decline, supporting the company’s long-term Alzheimer’s pipeline prospects. Article Title
• Positive Sentiment: Biogen received FDA approval for LEQEMBI IQLIK, a weekly at-home initiation dose for early Alzheimer’s patients, which could improve adoption and convenience. Article Title
• Neutral Sentiment: Biogen appointed Michael J. Parini as Chief Legal Officer, effective August 3, a governance update that adds legal and compliance leadership but does not change the core investment story. Article Title
• Negative Sentiment: Investors appear worried that diranersen’s Phase 2 data did not clearly validate the intended dose-response effect, raising execution risk as Biogen considers Phase 3 development. Article Title

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BIIB shares. JPMorgan Chase & Co. boosted their price target on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Truist Financial raised Biogen from a “hold” rating to a “buy” rating and raised their price objective for the stock from $190.00 to $235.00 in a research note on Monday. Argus upgraded Biogen to a “hold” rating in a report on Thursday, April 9th. Citigroup boosted their target price on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Piper Sandler restated an “overweight” rating on shares of Biogen in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $220.04.

Biogen Price Performance

The company’s 50-day moving average price is $198.83 and its 200-day moving average price is $188.66. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market cap of $29.12 billion, a P/E ratio of 21.16 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 13.6 earnings per share for the current fiscal year.

Institutional Trading of Biogen

Institutional investors have recently modified their holdings of the company. Empowered Funds LLC lifted its stake in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after acquiring an additional 2,777 shares in the last quarter. Focus Partners Wealth grew its stake in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Biogen during the 2nd quarter worth approximately $216,000. Cerity Partners LLC raised its holdings in shares of Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after purchasing an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after purchasing an additional 316 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.